These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25727194)

  • 1. High throughput screening of particle conditioning operations: II. Evaluation of scale-up heuristics with prokaryotically expressed polysaccharide vaccines.
    Noyes A; Huffman B; Berrill A; Merchant N; Godavarti R; Titchener-Hooker N; Coffman J; Sunasara K; Mukhopadhyay T
    Biotechnol Bioeng; 2015 Aug; 112(8):1568-82. PubMed ID: 25727194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High throughput screening of particle conditioning operations: I. System design and method development.
    Noyes A; Huffman B; Godavarti R; Titchener-Hooker N; Coffman J; Sunasara K; Mukhopadhyay T
    Biotechnol Bioeng; 2015 Aug; 112(8):1554-67. PubMed ID: 25728932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative high throughput analytics to support polysaccharide production process development.
    Noyes A; Godavarti R; Titchener-Hooker N; Coffman J; Mukhopadhyay T
    Vaccine; 2014 May; 32(24):2819-28. PubMed ID: 24576849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High throughput quantification of capsular polysaccharides for multivalent vaccines using precipitation with a cationic surfactant.
    Noyes A; Boesch A; Godavarti R; Titchener-Hooker N; Coffman J; Mukhopadhyay T
    Vaccine; 2013 Nov; 31(48):5659-65. PubMed ID: 24120674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated disposable small scale reactor for high throughput bioprocess development: a proof of concept study.
    Bareither R; Bargh N; Oakeshott R; Watts K; Pollard D
    Biotechnol Bioeng; 2013 Dec; 110(12):3126-38. PubMed ID: 23775295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPAEC-PAD quantification of Haemophilus influenzae type b polysaccharide in upstream and downstream samples.
    van der Put RM; de Haan A; van den IJssel JG; Hamidi A; Beurret M
    Vaccine; 2015 Nov; 33(48):6908-13. PubMed ID: 25045809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification of a conjugated polysaccharide vaccine using tangential flow diafiltration.
    Emami P; Motevalian SP; Pepin E; Zydney AL
    Biotechnol Bioeng; 2019 Mar; 116(3):591-597. PubMed ID: 30450582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polysaccharide purification from Haemophilus influenzae type b through tangential microfiltration.
    Albani SM; da Silva MR; Fratelli F; Junior CP; Iourtov D; Cintra Fde O; Takagi M; Cabrera-Crespo J
    Carbohydr Polym; 2015 Feb; 116():67-73. PubMed ID: 25458274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A methodological approach to scaling up fermentation and primary recovery processes to the manufacturing scale for vaccine production.
    Lee TS
    Vaccine; 2009 Oct; 27(46):6439-43. PubMed ID: 19577635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b.
    Verez-Bencomo V; Fernández-Santana V; Hardy E; Toledo ME; Rodríguez MC; Heynngnezz L; Rodriguez A; Baly A; Herrera L; Izquierdo M; Villar A; Valdés Y; Cosme K; Deler ML; Montane M; Garcia E; Ramos A; Aguilar A; Medina E; Toraño G; Sosa I; Hernandez I; Martínez R; Muzachio A; Carmenates A; Costa L; Cardoso F; Campa C; Diaz M; Roy R
    Science; 2004 Jul; 305(5683):522-5. PubMed ID: 15273395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and optimization of a chromatographic purification process for Streptococcus pneumoniae serotype 23F capsular polysaccharide by a Design of Experiments approach.
    Ji Y; Tian Y; Ahnfelt M; Sui L
    J Chromatogr A; 2014 Jun; 1348():137-49. PubMed ID: 24845825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel method for purification of Vi capsular polysaccharide produced by Salmonella enterica subspecies enterica serovar Typhi.
    Kothari S; Kothari N; Kim JA; Lee E; Yoon YK; An SJ; Jones C; Choe WS; Carbis R
    Vaccine; 2013 Oct; 31(42):4714-9. PubMed ID: 23994374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The design of a capsule polysaccharide conjugate vaccine against Campylobacter jejuni serotype HS15.
    Bertolo L; Ewing CP; Maue A; Poly F; Guerry P; Monteiro MA
    Carbohydr Res; 2013 Jan; 366():45-9. PubMed ID: 23261782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upflow anaerobic sludge blanket reactor--a review.
    Bal AS; Dhagat NN
    Indian J Environ Health; 2001 Apr; 43(2):1-82. PubMed ID: 12397675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a scaled-down aerobic fermentation model for scale-up in recombinant protein vaccine manufacturing.
    Farrell P; Sun J; Gao M; Sun H; Pattara B; Zeiser A; D'Amore T
    Vaccine; 2012 Aug; 30(38):5695-8. PubMed ID: 22633869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of serogroups in multivalent polysaccharide-based meningococcal vaccines: optimisation of hydrolysis conditions and chromatographic methods.
    Cook MC; Bliu A; Kunkel JP
    Vaccine; 2013 Aug; 31(36):3702-11. PubMed ID: 23764533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Design of a Clostridium difficile Carbohydrate-Based Vaccine.
    Monteiro MA
    Methods Mol Biol; 2016; 1403():397-408. PubMed ID: 27076143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a molecular size distribution method for polysaccharide vaccines.
    Clément G; Dierick JF; Lenfant C; Giffroy D
    Pharmeur Bio Sci Notes; 2014; 2014():40-59. PubMed ID: 25655242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clarification of vaccines: An overview of filter based technology trends and best practices.
    Besnard L; Fabre V; Fettig M; Gousseinov E; Kawakami Y; Laroudie N; Scanlan C; Pattnaik P
    Biotechnol Adv; 2016; 34(1):1-13. PubMed ID: 26657051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.